Chronic Lymphocytic Leukemia Clinical Trials

A listing of 70 Chronic Lymphocytic Leukemia clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Chronic Lymphocytic Leukemia

13 - 24 of 70

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 70 active clinical trials seeking participants for Chronic Lymphocytic Leukemia research studies. The states with the highest number of trials for Chronic Lymphocytic Leukemia participants are California, Ohio, Illinois and Michigan.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Research Study

Recruiting

Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Sinusitis

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Featured Trial

Stroke Clinical Study

Recruiting

A clinical study for people that suffer with Stroke

Conditions:

Stroke

Learn More

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT05006716

Recruiting

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/19/2025

Locations: University of Alabama At Birmingham Hospital, Birmingham, Alabama +116 locations

University of Alabama At Birmingham Hospital, Birmingham, Alabama

Western Regional Medical Center, Llc, Goodyear, Arizona

Mayo Clinic Phoenix, Phoenix, Arizona

Honor Health Research Institute, Scottsdale, Arizona

University of Arizona Cancer Center, Tucson, Arizona

University of California San Diego (Ucsd) Moores Cancer Center, La Jolla, California

Stanford Medicine, Palo Alto, California

UCLA Santa Monica Cancer Care, Santa Monica, California

Uchealth North, Fort Collins, Colorado

Mayo Clinic Jacksonville, Jacksonville, Florida

Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida

Tampa General Hospital Cancer Institute, Tampa, Florida

Augusta University, Augusta, Georgia

Southeastern Regional Medical Center, Newnan, Georgia

Midwestern Regional Medical Center, Zion, Illinois

University of Iowa Hospitals and Clinics, Iowa City, Iowa

Norton Cancer Institute Pavilion, Louisville, Kentucky

Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana

American Oncology Partners of Maryland Pa, Bethesda, Maryland

Dana Farber Cancer Institute, Boston, Massachusetts

Karmanos Cancer Institute, Detroit, Michigan

Mayo Clinic Rochester, Rochester, Minnesota

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada

Roswell Park Comprehensive Cancer Center, Buffalo, New York

Columbia University Medical Center, New York, New York

Weill Cornell Medical College Newyork Presbyterian Hospital, New York, New York

Memorial Sloan Kettering Cancer Center Mskcc, New York, New York

Tennesse Oncology Chattanooga, Chattanooga, Tennessee

Tennessee Oncology, Pllc Nashville, Nashville, Tennessee

Md Anderson Cancer Center, Houston, Texas

Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia

Fred Hutchinson Cancer Research Center, Seattle, Washington

Concord Repatriation General Hospital, Concord, New South Wales

Calvary Mater Newcastle, Waratah, New South Wales

Princess Alexandra Hospital, Woolloongabba, Queensland

St Vincents Hospital Melbourne, Fitzroy, Victoria

Peninsula Private Hospital, Frankston, Victoria

Austin Health, Heidelberg, Victoria

Peter Maccallum Cancer Centre, Melbourne, Victoria

The Alfred Hospital, Melbourne, Victoria

Linear Clinical Research, Nedlands, Western Australia

Perth Blood Institute, West Perth, Western Australia

Hospital Sirio Libanes Brasilia, Brasilia, Not set

Instituto de Pesquisa Em Saude Da Universidade de Caxias Do Sul, Caxias do Sul, Not set

Hospital Erasto Gaertner, Curitiba, Not set

Centro Gaucho Integrado de Oncologia Hospital Mae de Deus, Porto Alegre, Not set

Hospital Ernesto Dornelles, Porto Alegre, Not set

Real E Benemerita Associacao Portuguesa de Sao Paulo, Sao Paulo, Not set

Hospital Alemao Oswaldo Cruz, Sao Paulo, Not set

Hospital Nove de Julho Dasa, Sao Paulo, Not set

Instituto Dor de Pesquisa E Ensino Sao Paulo, Sao Paulo, Not set

Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, Sao Paulo, Not set

Hospital Santa Rita de Cassia Afecc, Vitoria, Not set

Cross Cancer Institute, Edmonton, Alberta

British Columbia Cancer Agency the Vancouver Centre, Vancouver, British Columbia

Princess Margaret Cancer Centre, Toronto, Ontario

Arthur Je Child Comprehensive Cancer Centre, Calgary, Not set

Chu de Quebec Universite Laval, Hopital de Lenfant Jesus, Centre Integre de Cancerologie (Cic), Quebec, Not set

Centre de Lutte Contre Le Cancer Institut Bergonie, Bordeaux, Not set

Hopital Estaing, Clermontferrand, Not set

Chu Henri Mondor, Creteil, Not set

Hopital Claude Huriez Chu Lille, Lille, Not set

Centre Leon Berard, Lyon Cedex, Not set

Institut Paoli Calmettes, Marseille, Not set

Chu Montpellier Hopital Saint Eloi, Montpellier, Not set

Hopital de La Pitie Salpetriere, Paris, Not set

Centre Henri Becquerel, Rouen Cedex, Not set

Arensia Exploratory Medicine Llc, Tbilisi, Not set

Universitatsklinikum Carl Gustav Carus An Der Technischen Universitat Dresden, Dresden, Not set

Uniklinik Koeln (Aoer), Koln, Not set

Universitares Krebszentrum Leipzig, Leipzig, Not set

Universitaetsklinikum Schleswig Holstein Campus Luebeck, Luebeck, Not set

Klinikum Johannes Gutenberg Universitaet Mainz, Mainz, Not set

Klinikum Grosshadern Ludwig Maximilians Universitat Munchen, Munchen, Not set

Universitaetsklinikum Ulm, Ulm, Not set

Policlinico Sorsola Malpighi, Aou Di Bologna, Bologna, Not set

Ospedale San Raffaele, Milano, Not set

Istituto Europeo Di Oncologia, Milano, Not set

Niguarda Cancer Center Division of Hematology, Milano, Not set

Fondazione Policlinico Universitario Agostino Gemelli, Roma, Not set

Centroricerche Cliniche Di Verona Srl, Verona, Not set

Aichi Cancer Center Hospital Clinical Oncology, Nagoya, Aichi

Chiba Cancer Center, Chibashi, Chiba

National Cancer Center Hospital East, Kashiwa, Chiba

Cancer Institute Hospital of Jfcr, Kotoku, Tokyo

Yokohama Municipal Citizens Hospital, YokohamaShi, Not set

Inje University Busan Paik Hospital, BusanjinGu, Busan Gwang'yeogsi

Pusan National University Hospital, SeoGu, Busan Gwang'yeogsi

Samsung Medical Center, GangnamGu, Seoul Teugbyeolsi

The Catholic University of Korea, Seoul St Marys Hospital, SeochoGu, Seoul Teugbyeolsi

Severance Hospital Yonsei University Health System, SeodaemunGu, Seoul Teugbyeolsi

Seoul National University Hospital, Seoul, Seoul Teugbyeolsi

Asan Medical Center, SongpaGu, Seoul Teugbyeolsi

The Institute of Oncology, Arensia Exploratory Medicine, Chisinau, Not set

Hospital Universitario Vall Dhebron, Barcelona, Not set

Hospital de La Santa Creu I Sant Pau, Barcelona, Not set

Hospital General Universitario Gregorio Maranon, Madrid, Not set

Md Anderson Cancer Center Madrid Spain, Madrid, Not set

Hospital Universitario Fundacion Jimenez Diaz, Madrid, Not set

Hospital Universitario La Paz, Madrid, Not set

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Not set

Hospital Clinico Universitario de Valencia, Valencia, Not set

Sahlgrenska University Hospital Hematology, Goteborg, Not set

Karolinska Universitetssjukhuset Solna, Stockholm, Not set

Uppsala Akademiska Sjukhus, Uppsala, Not set

Ankara University, Abidinpaa, Not set

Dr Abdurrahman Yurtaslan Research and Training Hospital, Ankara, Not set

Dokuz Eylul University, Balcova, Not set

Erciyes University, Kayseri, Not set

Sakarya Training and Research Hospital, Sakarya, Not set

Ondokuz Mayis University, Samsun, Not set

Edinburgh Cancer Centre, Edinburgh, Not set

Churchill Hospital Oxford University Hospital Nhs Trust, Headington, Not set

St Jamess University Hospital, Leeds, Not set

Freeman Hospital, NewCastle Upon Tyne, Not set

Nottingham University Hospitals Nhs Trust, Nottingham, Not set

Derriford Hospital, Plymouth, Not set

Conditions: B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-hodgkin Lymphoma, Waldenström Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma

Learn More ›

Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study

NCT05718869

Recruiting

This phase II trial tests how well tafasitamab and zanubrutinib works in treating patients with newly diagnosed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein that signals cancer cells to multiply. This may stop the growth and spread of cancer cells. Givin... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/18/2025

Locations: City of Hope Medical Center, Duarte, California +2 locations

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Learn More ›

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

NCT06876649

Recruiting

The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the oppor... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/18/2025

Locations: Sylvester Comprehensive Cancer Center, Miami, Florida +35 locations

Sylvester Comprehensive Cancer Center, Miami, Florida

Florida Cancer Specialists, Sarasota, Florida

The Emory Clinic, Atlanta, Georgia

Northwestern University, Chicago, Illinois

Dana-Farber Cancer Institute, Boston, Massachusetts

Mayo Clinic- Minnesota, Rochester, Minnesota

University Of Nebraska Medical Center, Omaha, Nebraska

Cayuga Cancer Center, Ithaca, New York

Northwell Health, Lake Success, New York

Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York, New York

Duke University Medical Center, Durham, North Carolina

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

University of Pennsylvania Hospital, Philadelphia, Pennsylvania

Tennessee Oncology, Nashville, Tennessee

University of Texas MD Anderson Cancer Center, Houston, Texas

Swedish Cancer Institute, Seattle, Washington

Medical College of Wisconsin, Milwaukee, Wisconsin

Flinders Medical Centre, Adelaide, South Australia

Peter MacCallum Cancer Centre, Melbourne, Victoria

Linear Clinical Research, Victoria, Not set

CHU de Nantes - Hotel Dieu, Nantes Cedex 1, Loire Atlantique

Ospedale San Raffaele, Milano, Lombardia

IRCCS-AOU di Bologna-Policlinico S.Orsola-Malpighi, Bologna, Not set

Tokai University Hospital- Isehara Campus, Isehara, Kanagawa

National Cancer Center Hospital, Cho-ku, Tokyo

Nagoya Medical Center, Aichi-Ken, Not set

National Hospital Organization Kyushu Cancer Center, Fukuoka, Not set

Tohoku University Hospital, Miyagi-Ken, Not set

Hokkaido University Hospital, Sapporoshi, Not set

Seoul National University Hospital, Seoul, Korea

Pratia MCM Krakow, Krakow, Not set

Instytut Hermatologii I Transfuzjologii, Warsaw, Not set

Derriford Hospital, Plymouth, Devon

Churchill Hospital, Oxford, Oxfordshire

St James's University Hospital, Leeds, West Yorkshire

Conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma

Learn More ›

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

NCT05618028

Recruiting

B-cell malignancies are a group of cancers of B lymphocytes, a type of white blood cell responsible for fighting infections. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-525 as a monotherapy. ABBV-525 is an investigational drug being developed for the treatment of B-Cell Malignancies. Study doctors put the participants in groups called treatment arms. Participants will receive ABBV-525 at different doses. Approximately 150 adult... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/15/2025

Locations: University of California Los Angeles /ID# 246357, Los Angeles, California +33 locations

University of California Los Angeles /ID# 246357, Los Angeles, California

Yale University School of Medicine /ID# 259081, New Haven, Connecticut

Mount Sinai Medical Center-Miami Beach /ID# 248251, Miami Beach, Florida

Fort Wayne Medical Oncology and Hematology, Inc /ID# 250113, Fort Wayne, Indiana

Indiana University Melvin and Bren Simon Comprehensive Cancer Center /ID# 259872, Indianapolis, Indiana

Tulane Cancer Center Clinic /ID# 249586, New Orleans, Louisiana

START Midwest /ID# 252359, Grand Rapids, Michigan

Memorial Sloan Kettering Cancer Center-Koch Center /ID# 245459, New York, New York

Levine Cancer Institute /ID# 246363, Charlotte, North Carolina

University Of Cincinnati Medical Center /ID# 262288, Cincinnati, Ohio

University of Texas MD Anderson Cancer Center /ID# 245463, Houston, Texas

University of Utah Health Hospital /ID# 259924, Salt Lake City, Utah

Northwest Medical Specialties - Tacoma /ID# 260376, Tacoma, Washington

Liverpool Hospital /ID# 260191, Liverpool, New South Wales

Monash Health - Monash Medical Centre /ID# 246366, Clayton, Victoria

The Alfred Hospital /ID# 248592, Melbourne, Victoria

UZ Gent /ID# 246462, Gent, Oost-Vlaanderen

Universitair Ziekenhuis Leuven /ID# 246461, Leuven, Vlaams-Brabant

CHRU Lille - Hopital Claude Huriez /ID# 252054, Lille, Nord

IUCT Oncopole /ID# 259409, Toulouse Cedex 9, Occitanie

Charite Universitaetsmedizin Berlin Campus Virchow-Klinikum /ID# 252062, Berlin, Not set

Shamir Medical Center /ID# 257711, Beer Ya'akov, HaMerkaz

The Chaim Sheba Medical Center /ID# 251442, Ramat Gan, Tel-Aviv

Hadassah Medical Center-Hebrew University /ID# 251441, Jerusalem, Yerushalayim

Rabin Medical Center /ID# 257665, Petah Tikva, Not set

Asan Medical Center /ID# 266341, Seoul, Seoul Teugbyeolsi

Institut Català d'Oncologia (ICO) - L'Hospitalet /ID# 246537, L'Hospitalet de Llobregat, Barcelona

Hospital Universitario Vall d'Hebron /ID# 245475, Barcelona, Not set

Hospital Clinic de Barcelona /ID# 246543, Barcelona, Not set

Hospital Universitario Ramon y Cajal /ID# 246540, Madrid, Not set

Hospital Universitario 12 de Octubre /ID# 246538, Madrid, Not set

Leeds Teaching Hospitals NHS Trust /ID# 245470, Leeds, West Yorkshire

The Royal Marsden NHS Foundation Trust /ID# 250324, London, Not set

The Christie Hospital /ID# 250325, Manchester, Not set

Conditions: Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma

Learn More ›

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686

Recruiting

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/15/2025

Locations: City of Hope Cancer Center, Duarte, California +173 locations

City of Hope Cancer Center, Duarte, California

University of California San Diego Medical Center, La Jolla, California

University of California Los Angeles, Los Angeles, California

St. Joseph Hospital Center for Cancer Prevention and Treatment, Orange, California

Stanford University Medical Center, Stanford, California

Stanford University, Stanford, California

Norwalk Medical Group, Norwalk, Connecticut

Northwest Georgia Oncology Centers PC, Marietta, Georgia

Northwestern University Hospital, Chicago, Illinois

Indiana University, Goshen, Indiana

Kansas University Medical Center, Westwood, Kansas

Louisville Oncology Suburban - Norton Cancer Institute, Louisville, Kentucky

Dana Farber Cancer Center, Boston, Massachusetts

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

Battle Creek Health Systm, Battle Creek, Michigan

Karmanos Cancer Institute - Wayne State University, Detroit, Michigan

Washington University, Saint Louis, Missouri

Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

Hackensack University Medical Center, Hackensack, New Jersey

Weill Medical College of Cornell University, New York, New York

Memorial Sloan-Kettering Cancer Center, New York, New York

Southeastern Medical Oncology Center, Goldsboro, North Carolina

The Ohio State University- James Cancer Hospital, Columbus, Ohio

Willamette Valley Cancer Center, Eugene, Oregon

Kaiser Permanente, Portland, Oregon

University of Pennsylvania Medical Center, Philadelphia, Pennsylvania

Avera Medical Group, Sioux Falls, South Dakota

MD Anderson Cancer Center - University of Texas, Houston, Texas

University of Virginia, Charlottesville, Virginia

University of Washington, Seattle, Washington

West Virginia University, Morgantown, West Virginia

University of Wisconsin Carbone Cancer Center - Wisconsin Institute for Medical Research, Madison, Wisconsin

CEMIC Saavedra, Ciudad Autonoma Buenos Aires, Not set

Fundaleu, Ciudad de Buenos Aires, Not set

Royal Adelaide Hospital, Adelaide, Not set

John Fawkner Cancer Trial Centre, Coburg, Not set

Concord Hospital, Concord, Not set

Austin Health, Heidelberg, Not set

Peter MacCallum Cancer Institute, Melbourne, Not set

Royal Perth Hospital, Perth, Not set

Alfred Hospital, Prahran, Not set

Adventist Health Care Limited trading as San Clinical Trials Unit, Wahroonga, Not set

UZA, Antwerp, Not set

A.Z. Sint Jan, Brugge, Not set

UCL - Saint Luc, Brussels, Not set

UZ Gent - departement oncologie, Gent, Not set

UZ Leuven Gasthuisberg, Leuven, Not set

UCL Mont-Godinne, Yvoir, Not set

Ministerio da Saude Instituto Nacional do Cancer, Rio De Janeiro, Not set

Santa Casa da Misericórdia da Bahia - Hospital Santa Isabel, Salvador, Not set

Instituto de Ensino e Pesquisa São Lucas, Sao Paulo, Not set

Jewish General Hospital, Montreal, Quebec

Peking University People s Hospital, Beijing, Not set

Peking University Third Hospital, Beijing, Not set

Peking University First Hospital, Beijing, Not set

West China Hospital Sichuan University, Chengdu, Not set

Fujian Medical University, Fuzhou, Not set

Sun Yat-sen University Cancer Hospital, Guangzhou, Not set

Zhejiang University First Hospital, Hangzhou, Not set

Ruijin Hospital, Shanghai, Not set

Tangdu hospital the Fourth Military Medical, Shanxi, Not set

The First Affliated Hospital of Soochow University, Suzhou, Not set

The Institute of Hematological disease, Tianjin, Not set

Wuhan Union Hospital, Wuhan, Not set

Fundacion Santa Fe, Bogota, Not set

Fundacion Oftalmologica de Santander - FOSCAL, Floridablanca, Not set

Fakultni nemocnice Brno, Interni hematologicka a onkologicka klinika, Brno, Not set

Fakultni nemocnice Kralovske Vinohrady - Interni hematologicka klinika, Praha 10, Not set

Vseobecna fakultni nemocnice v Praze - I. interni klinika - klinika hematologie, Praha 2, Not set

Hopital Henri Mondor, Creteil, Not set

Hôpital E. Muller, Mulhouse, Not set

Hopital Necker Enfants Malades, Paris cedex 15, Not set

HOPITAL SAINT LOUIS - Hematology / Oncology, Paris, Not set

Hopital Haut Leveque Service Maladie Du Sang, Pessac, Not set

CH LYON SUD - Hematology, Pierre Benite, Not set

CHU de Tours, Tours, Not set

Vivantes Klinikum Spandau-Klinik f. Innere Medizin Hämatologie/Onkologie/Gastroenterologie - Germany, Berlin, Not set

Universitätsklinikum Carl Gustav Carus; Med. Klinik und Poliklinik I - Hämatologische Ambulanz, Haus, Dresden, Not set

Universitätsklinikum Essen; Klinik f. Hämatologie- Germany, Essen, Not set

Justus-Liebig-Universitaet - Medizinische Klinik IV, Haematologie, Gießen, Not set

Universitätsklinikum Heidelberg Med. Klinik IV, Heidelberg, Not set

Universitätsklinikum des Saarlandes, Homburg/Saar, Not set

Gemeinschaftspraxis Dres. Uhle/Müller/Kröning/Jentsch-Ullrich - Germany, Magdeburg, Not set

OnkoNet Marburg GmbH, Marburg, Not set

Universitätsklinikum für Innere Med. III_Hämatologie, Onkologie...- Germany, Ulm, Not set

Laiko General Hospital - 1st department of Internal Medicine, Athens, Not set

G Papanikolaou Hospital of Thessaloniki, Thessalonikis, Not set

Semmelweis Egyetem, I. Belgyogyaszati Klinika, Budapest N/a, Not set

Szegedi Tudomanyegyetem II. Belgyogyaszati Klinika, Szeged, Not set

St James's Hospital, Dublin, Not set

Haemek Medical Center, Afula, Not set

Hillel Yaffe Medical Center - Oncology, Hadera, Not set

Rambam Health Care Campus, Haifa, Not set

Rabin Medical Center Beilinson Campus, Petah Tikva, Not set

Sheba Medical Center, Ramat-Gan, Not set

Tel Aviv Sourasky Medical Center, Tel Aviv, Not set

ASST Grande Ospedale Metropolitano Niguarda, Milano, Not set

DIPARTIMENTO DI BIOTECNOLOGIE CELLULARI ED EMATOLOGIA - UNIVERSITà ''LA SAPIENZA'', Roma, Not set

A.O.Citta della Salute e della Scienza di Torino, Torino, Not set

Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo ku, Not set

Hiroshima University Hospital, Hiroshima shi, Not set

Hokkaido University Hospital, Sapporo-shi, Not set

National Cancer Center, Goyang-Si, Not set

The Catholic University of Korea Seoul St Mary s Hospital, Seoul, Not set

Oaxaca Site Management Organization S.C., Oaxaca, Not set

VU medisch centrum - Afd.Interne - INT, Amsterdam, Not set

Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im Ks B Markiewicza, Brzozow, Not set

Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich, Chorzow, Not set

Uniwersyteckie Centrum Kliniczne, Gdansk, Not set

Pratia MCM Krakow, Krakow, Not set

Oddzial Hematologii, Opole, Not set

Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka, Slupsk, Not set

Katedra I Klinika Hematologii Nowotworow Krwi I Transplantacji Szpiku, Wroclaw, Not set

Instituto Portugues de Oncologia, Lisboa, Not set

Hospital De Santa Maria, Lisbon, Not set

Instituto Portugues de Oncologia, Porto, Not set

Auxilio Mutuo Cancer Center, San Juan, Not set

Arkhangelsk Regional Clinical Hospital, Arkhangelsk, Not set

Chelyabinsk Regiona Onc. Center, Chelyabinsk, Not set

Emergency Hospital of Dzerzhinsk, Dzerzhinsk, Not set

Cancer Research Center, Moscow N/a, Not set

S.P. Botkin Moscow City Clinical Hospital, Moscow, Not set

Regional Clinical Hospital n.a.Semashko, Nizhni Novgorod, Not set

Medical Scientific Radiology - Center, Obninsk, Not set

Perm Medical Sanitary Unit#1, Perm, Not set

Republican Hospital named by V.A.Baranova, Petrozavodsk, Not set

Rostov Research Institute of Oncology, Rostov-Na-Donu, Not set

Ryazan Regional Clinical Hospital, Ryazan, Not set

Leningrad region clinical hospital, Saint, Not set

Samara Region Clinical Hospital, Samara, Not set

Federal Center of Heart, Blood and Endocrinology, Sankt-Peterburg, Not set

Oncological dispensary #2, Sochi, Not set

City Clinical Oncology Dispensary, St. Petersburg, Not set

Clinical Research Institute of Hematology and Transfusiology, St.-Petersburg, Not set

Oncology Dispensary of Komi Republic, Syktyvkar, Not set

Hospital Vall d'Hebron, Barcelona N/a, Not set

Inst. Cat. Doncologia-H Duran I Reynals, L'hospitalet De Llobregat, Not set

Hosp. Univ. de La Princesa, Madrid, Not set

Hosp. Gral. Univ. Gregorio Maranon, Madrid, Not set

Hosp. Univ. Infanta Leonor, Madrid, Not set

Fundacion Jimenez Diaz, Madrid, Not set

Clinica Universitaria de Navarra, Pamplona N/a, Not set

Hospital Clinico Universitario Salamanca, Salamanca, Not set

Sahlgrenska University hospital, Hematology Dept, Göteborg, Not set

Skanes universitetssjukhus, Lund, Not set

Karolinska Universitetssjukhuset Solna, Centrum för Hematologi, Stockholm, Stockholm, Not set

Changhua Cristian Hospital, Changhua County, Not set

Ankara University, Ankara, Not set

American Hospital, Istanbul, Not set

Istanbul University, Istanbul, Not set

Dokuz Eylul Universitesi Tip Fakultesi, Izmir, Not set

Erciyes University, Kayseri, Not set

Communal Nonprofit Enterprise 'Cherkasy Regional Oncology Dispensary Of Cherkasy Regional Council', Cherkasy, Not set

Dnepropetrovsk City Clinical Hospital #4, Regional Hematology Center, Dnepropetrovsk, Not set

SI Grigoriev Institute for Medical Radiology National Academy of Medical Science of Ukraine, Kharkiv, Not set

Khmelnitskiy Regional Hospital, Hematology Department, Khmelnitskiy, Not set

State Institution Scientific Center for Radiation Medicine Academy of Medical Sciences of Ukraine, Kiev, Not set

Institute of Blood Pathology and Transfusion Medicine of AMS of Ukraine, Lviv, Not set

Vinnytsya Regional Clinical Hospital named after M.I.Pirogov, Vinnitsa, Not set

University Hospitals Birmingham NHS Trust,, Birmingham, Not set

Royal Bournemouth Hospital, Bournemouth, Not set

Colchester Hospital University NHS, Colchester, Not set

Beatson West Of Scotland Cancer Centre, Glasgow, Not set

St James's Institute of Oncology, Leeds, Not set

Leicester Royal Infirmary - Haematology, Leicester, Not set

St Bartholomew's Hospital - Dept of Haematology, London, Not set

University College London Hospitals NHSFT, London, Not set

Kings College Hospital, London, Not set

Christie Hospital, Manchester, Not set

Nottingham University Hospitals NHS Trust, Nottingham, Not set

Derriford Hospital, Plymouth, Not set

Royal Hallamshire Hospital, Sheffield, Not set

Southampton General Hospital, Southampton, Not set

Royal Marsden Hospital (Sutton), Sutton, Not set

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Waldenstrom Macroglobulinemia, Chronic Graft Versus Host Disease

Learn More ›

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

NCT05458297

Recruiting

The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). This study will also evaluate zilovertamab vedotin as monotherapy and in combination with respect to objective response rate. * Cohort A: Participants with relapsed or refractory MCL r... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/14/2025

Locations: Alaska Oncology and Hematology ( Site 0037), Anchorage, Alaska +108 locations

Alaska Oncology and Hematology ( Site 0037), Anchorage, Alaska

Banner MD Anderson Cancer Center ( Site 0040), Gilbert, Arizona

Banner MD Anderson Cancer Center - University Medical Center Phoenix-Medical Oncology ( Site 0036), Phoenix, Arizona

University of Colorado Anschutz Medical Campus-The Center for Cancer and Blood Disorders ( Site 0008), Aurora, Colorado

Cancer Care Specialists of Illinois ( Site 0031), Decatur, Illinois

University of Kansas Medical Center-Division of Hematologic Malignancies and Cellular Therapeutics ( Site 0038), Fairway, Kansas

Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0007), Saint Matthews, Kentucky

Greenebaum Comprehensive Cancer Center-Hematology & Multiple Myeloma ( Site 0010), Baltimore, Maryland

Tufts Medical Center ( Site 0024), Boston, Massachusetts

Massachusetts General Hospital ( Site 0018), Boston, Massachusetts

Dana-Farber Cancer Institute-Lymphoma ( Site 0026), Boston, Massachusetts

University of Michigan ( Site 0009), Ann Arbor, Michigan

Henry Ford Hospital ( Site 0035), Detroit, Michigan

Icahn School of Medicine at Mount Sinai ( Site 0023), New York, New York

Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0014), Fargo, North Dakota

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0004), Columbus, Ohio

Avera Cancer Institute- Research ( Site 0011), Sioux Falls, South Dakota

Medical Oncology Associates, PS ( Site 0005), Spokane, Washington

University of Wisconsin Hospitals and Clinics-Carbone Cancer Center ( Site 0030), Madison, Wisconsin

MEDICAL COLLEGE OF WISCONSIN ( Site 0021), Milwaukee, Wisconsin

Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 1807), Natal, Rio Grande Do Norte

Instituto Nacional de Câncer - INCA-Divisão de Pesquisa Clínica e Desenvolvimento Tecnológico HC1 ( Site 1809), Rio de Janeiro, Not set

ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 1808), Sao Paulo, Not set

Hospital Paulistano-Americas Oncologia ( Site 1805), Sao Paulo, Not set

BC Cancer Vancouver-Clinical Trials Unit ( Site 0201), Vancouver, British Columbia

The Moncton Hospital-Oncology ( Site 0211), Moncton, New Brunswick

QEII Health Sciences Centre - Victoria General Site ( Site 0213), Halifax, Nova Scotia

Lawson Health Research Institute - London Health Sciences Ce-London Regional Cancer Program ( Site 0203), London, Ontario

Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0200), Toronto, Ontario

Jewish General Hospital ( Site 0202), Montreal, Quebec

Allan Blair Cancer Centre-Care Services ( Site 0208), Regina, Saskatchewan

IC La Serena Research ( Site 1909), La Serena., Coquimbo

Centro de Estudios Clínicos SAGA-CECSAGA ( Site 1907), Santiago., Region M. De Santiago

Clínica Inmunocel ( Site 1910), Santiago, Region M. De Santiago

Clínica Alemana de Santiago ( Site 1903), Santiago, Region M. De Santiago

Beijing Cancer hospital ( Site 1200), Beijing, Beijing

Zhujiang Hospital ( Site 1207), Guangzhou, Guangdong

Southern Medical University Nanfang Hospital ( Site 1202), Guangzhou, Guangdong

Sun Yat-sen University Cancer Center ( Site 1201), Guangzhou, Guangdong

Henan Cancer Hospital-hematology department ( Site 1212), Zhengzhou, Henan

Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 1210), Wuhan, Hubei

Tongji Hospital Tongji Medical,Science & Technology ( Site 1221), Wuhan, Hubei

The First Affiliated Hospital of Soochow University-hematology department ( Site 1218), Suzhou, Jiangsu

The Affiliated Hospital of Xuzhou Medical College ( Site 1223), Xuzhou, Jiangsu

The First Affiliated Hospital of Nanchang University ( Site 1204), Nanchang, Jiangxi

Jiangxi Provincial Cancer Hospital ( Site 1213), Nanchang, Jiangxi

Jilin Province Tumor Hospital-oncology department ( Site 1220), Chuangchun, Jilin

Fudan University Shanghai Cancer Center ( Site 1208), Shanghai, Shanghai

West China Hospital of Sichuan University-Head and Neck Oncology ( Site 1206), Cheng Du, Sichuan

The First Affiliated Hospital, Zhejiang University ( Site 1211), Hangzhou, Zhejiang

Zhejiang Cancer Hospital ( Site 1214), Hangzhou, Zhejiang

Fakultní nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0300), Brno, Brno-mesto

Fakultni nemocnice Ostrava-Klinika Hematoonkologie ( Site 0301), Ostrava, Moravskoslezsky Kraj

Vseobecna fakultni nemocnice v Praze-I. Interní klinika - klinika hematologie ( Site 0302), Praha 2, Not set

North Estonia Medical Centre Foundation ( Site 0401), Tallinn, Harjumaa

Universitaetsklinikum Ulm. ( Site 0502), Ulm, Baden-Wurttemberg

Universitaetsklinikum Koeln ( Site 0506), Köln, Nordrhein-Westfalen

St. James's Hospital ( Site 0600), Dublin, Not set

Emek Medical Center-Hematology Unit ( Site 0705), Afula, Not set

Soroka Medical Center-Hematology Department ( Site 0707), Be'er Sheva, Not set

Rambam Health Care Campus-Hematology and Bone Marrow Transplantation ( Site 0706), Haifa, Not set

Carmel Hospital ( Site 0709), Haifa, Not set

Hadassah Medical Center ( Site 0701), Jerusalem, Not set

Galilee Medical Center ( Site 0710), Nahariya, Not set

Sheba Medical Center-Hemato Oncology ( Site 0700), Ramat Gan, Not set

IRCCS - AOU di Bologna-SSD: Diagnosi e terapie dei linfomi e delle sindromi linfoproliferative cron ( Site 0800), Bologna, Emilia-Romagna

Humanitas-U.O di Oncologia medica ed Ematologia ( Site 0802), Rozzano, Milano

Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare -Azienda Ospedaliera Nazionale SS. Ant ( Site 0803), Alessandria, Not set

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -ISTITUTO DI EMATOLOGIA ( Site 0804), Roma, Not set

National Hospital Organization Nagoya Medical Center ( Site 1108), Nagoya, Aichi

Hokkaido University Hospital ( Site 1104), Sapporo, Hokkaido

Tokai University Hospital ( Site 1100), Isehara, Kanagawa

Tohoku University Hospital ( Site 1106), Sendai-shi, Miyagi

Kindai University Hospital ( Site 1102), Sayama, Osaka

National Cancer Center Hospital ( Site 1103), Chuo-ku, Tokyo

Cancer Institute Hospital of JFCR ( Site 1101), Koto, Tokyo

Kyushu University Hospital ( Site 1105), Fukuoka, Not set

Okayama University Hospital ( Site 1107), Okayama, Not set

Seoul National University Hospital ( Site 1300), Seoul, Not set

Samsung Medical Center ( Site 1301), Seoul, Not set

Centro Medico Monte Carmelo ( Site 1702), Arequipa, Ariqipa

INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS ( Site 1700), Lima, Not set

Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumat-Oddiał Hematologii Ogólnej ( Site 1008), Łódź, Lodzkie

Centrum Onkologii Ziemi Lubelskiej-Oddzial Hematologiczny ( Site 1006), Lublin, Lubelskie

Pratia MCM Krakow ( Site 1001), Krakow, Malopolskie

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( Site 1002), Warszawa, Mazowieckie

Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Hematologii i Transplantacji S ( Site 1010), Kielce, Swietokrzyskie

Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA w Olsztynie-Oddzial Kliniczny Hematologii ( Site 1007), Olsztyn, Warminsko-mazurskie

Champalimaud Foundation ( Site 2002), Lisbon, Lisboa

Unidade Local de Saude de Braga - Hospital de Braga ( Site 2001), Braga, Not set

Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 2000), Porto, Not set

National Cancer Centre Singapore ( Site 1500), Singapore, Central Singapore

Instituto Catalan de Oncologia - Hospital Duran i Reynals-Haematology Department ( Site 4003), L'Hospitalet Del Llobregat, Barcelona

Hospital Universitari Vall d'Hebron ( Site 4004), Barcelona, Cataluna

MD Anderson Cancer Center ( Site 4006), Madrid, Madrid, Comunidad De

Clinica Universidad de Navarra ( Site 4005), Pamplona, Navarra

Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca-Hematology ( Site 4001), Salamanca, Not set

Skånes Universitetssjukhus Lund ( Site 5000), Lund, Skane Lan

Akademiska sjukhuset-Blod- och tumörsjukdomar ( Site 5002), Uppsala, Uppsala Lan

Sahlgrenska Universitetssjukhuset ( Site 5003), Gothenburg, Vastra Gotalands Lan

Mega Medipol-Hematology ( Site 6009), Stanbul, Istanbul

Ankara Universitesi Tip Fakultesi Hastanesi-hematology ( Site 6001), Ankara, Not set

Trakya University ( Site 6005), Edirne, Not set

Ege Universitesi Hastanesi ( Site 6002), İzmir, Not set

Ondokuz Mayıs Universitesi-Oncology department ( Site 6004), Samsun, Not set

The Royal Cornwall Hospital-Haematology ( Site 7006), Truro, Cornwall

University College London Hospital ( Site 7001), London, London, City Of

The Churchill Hospital ( Site 7002), Oxford, Oxfordshire

The Christie NHS Foundation Trust ( Site 7007), Manchester, Not set

Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma

Learn More ›

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT05091424

Recruiting

This study will assess the safety, tolerability, pharmaokinetics, and preliminary efficacy of mosunetuzumab (Lunsumio) monotherapy in participants with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed by the treating physician to continue their BTKi throughout the screening period and for the first two cycles of mosunetuzumab... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/13/2025

Locations: Mayo Clinic Rochester, Rochester, Minnesota +22 locations

Conditions: Chronic Lymphocytic Leukemia

Learn More ›

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

NCT06136559

Recruiting

The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy. The primary hypotheses are that (1) nemtabrutinib is non-inferior to ibrutinib or acalabrutinib with respect to objective response rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 by blinded independent centra... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/12/2025

Locations: USA Mitchell Cancer Institute ( Site 0014), Mobile, Alabama +182 locations

USA Mitchell Cancer Institute ( Site 0014), Mobile, Alabama

Arizona Oncology Associates - NAHOA ( Site 8007), Prescott, Arizona

Alta Bates Summit Medical Center ( Site 0004), Berkeley, California

Moores Cancer Center ( Site 0003), La Jolla, California

Saint Joseph Hospital ( Site 0026), Denver, Colorado

Lutheran Medical Center ( Site 0027), Golden, Colorado

Intermountain Health St. Mary's Regional Hospital ( Site 0025), Grand Junction, Colorado

Eastern CT Hematology & Oncology Associates ( Site 0033), Norwich, Connecticut

Clermont Oncology Center ( Site 0046), Clermont, Florida

Florida Cancer Specialists - South ( Site 7001), Fort Myers, Florida

Florida Cancer Specialists - East ( Site 7002), West Palm Beach, Florida

Parkview Research Center at Parkview Regional Medical Center ( Site 0002), Fort Wayne, Indiana

University of Iowa-Holden Comprehensive Cancer Center ( Site 0017), Iowa City, Iowa

Saint Elizabeth Healthcare ( Site 0041), Edgewood, Kentucky

Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011), Grand Rapids, Michigan

Regions Hospital ( Site 0042), Saint Louis Park, Minnesota

MidAmerica Cancer Care, LLC ( Site 0043), Kansas City, Missouri

Summit Medical Group Cancer Center ( Site 0007), Florham Park, New Jersey

John Theurer Cancer Center at Hackensack University Medical Center ( Site 0016), Hackensack, New Jersey

Roswell Park Cancer Institute ( Site 0023), Buffalo, New York

Consultants in Medical Oncology and Hematology (CMOH) ( Site 8002), Broomall, Pennsylvania

Cancer Care Associates Of York ( Site 0005), York, Pennsylvania

Tennessee Oncology-Chattanooga ( Site 0045), Chattanooga, Tennessee

TENNESSEE ONCOLOGY ( Site 0031), Nashville, Tennessee

Texas Oncology - Central/South Texas ( Site 8008), Austin, Texas

The Center for Cancer and Blood Disorders ( Site 0032), Fort Worth, Texas

Texas Oncology - San Antonio ( Site 8006), San Antonio, Texas

Texas Oncology - Northeast Texas ( Site 8012), Tyler, Texas

University of Virginia Cancer Center ( Site 0040), Charlottesville, Virginia

Inova Schar Cancer Institute ( Site 0015), Fairfax, Virginia

Virginia Commonwealth University (VCU) Medical Center ( Site 0030), Richmond, Virginia

Medical Oncology Associates, PS (dba Summit Cancer Centers) ( Site 0010), Spokane, Washington

University Hospital and UW Health Clinics ( Site 0006), Madison, Wisconsin

Royal North Shore Hospital ( Site 2806), St Leonards, New South Wales

AZ Sint-Maarten, Campus Leopoldstraat 2 ( Site 0205), Mechelen, Antwerpen

UZ Leuven-Hematology ( Site 0200), Leuven, Vlaams-Brabant

Hospital 9 De Julho ( Site 2206), São Paulo, Sao Paulo

Instituto Nacional de Câncer - INCA ( Site 2201), Rio de Janeiro, Not set

Hospital Paulistano-Americas Oncologia ( Site 2202), Sao Paulo, Not set

BC Cancer Kelowna ( Site 0112), Kelowna, British Columbia

BC Cancer Victoria ( Site 0109), Victoria, British Columbia

William Osler Health System ( Site 0103), Brampton, Ontario

The Ottawa Hospital - General Campus ( Site 0102), Ottawa, Ontario

McGill University Health Centre ( Site 0106), Montréal, Quebec

Centre intégré de santé et de services sociaux du Bas Saint-Laurent- Hôpital régional de Rimouski ( Site 0100), Rimouski, Quebec

Bradfordhill-Clinical Area ( Site 2310), Santiago., Region M. De Santiago

FALP-UIDO ( Site 2300), Santiago, Region M. De Santiago

Clínica Alemana de Santiago-Unidad de Investigaciones ( Site 2306), Santiago, Region M. De Santiago

Anhui Provincial Cancer Hospital ( Site 2001), Hefei, Anhui

Peking University First Hospital ( Site 2022), Beijing, Beijing

Peking University Third Hospital-Hematology ( Site 2011), Beijing, Beijing

Chongqing University Cancer Hospital ( Site 2041), Chongqing, Chongqing

Southern Medical University Nanfang Hospital-Department of Hematopathology ( Site 2006), Guangzhou, Guangdong

Sun Yat-sen University Cancer Center ( Site 2028), Guangzhou, Guangdong

Liuzhou People's Hospital ( Site 2029), Liuzhou, Guangxi

Guangxi Medical University Affiliated Tumor Hospital ( Site 2004), Nanning, Guangxi

The Affiliated Hospital of Guizhou Medical University ( Site 2024), Guiyang, Guizhou

Hainan General Hospital ( Site 2018), Haikou, Hainan

Wuhan Union Hospital ( Site 2015), Wuhan, Hebei

Henan Cancer Hospital-hematology department ( Site 2025), Zhengzhou, Henan

Tongji Hospital Affiliated to Tongji Medical College of HUST ( Site 2016), Wuhan, Hubei

Hunan Cancer Hospital ( Site 2020), Changsha, Hunan

The Second Xiangya Hospital of Central South University ( Site 2010), Changsha, Hunan

Jiangsu Province Hospital ( Site 2000), Nanjing, Jiangsu

The First Affliated Hospital of Suzhou University ( Site 2027), Suzhou, Jiangsu

The Affiliated Hospital of Xuzhou Medical College ( Site 2013), Xuzhou, Jiangsu

The First Affiliated Hospital of Nanchang University ( Site 2023), Nanchang, Jiangxi

Jiangxi Provincial Cancer Hospital ( Site 2009), Nanchang, Jiangxi

The First Hospital of Jilin University-Hematology ( Site 2030), Changchun, Jilin

Shaanxi provincial people's hospital ( Site 2012), Xian, Shaanxi

Shandong Cancer Hospital ( Site 2003), Jinan, Shandong

Shanxi Cancer Hospital ( Site 2033), Taiyuan, Shanxi

West China Hospital, Sichuan University-Head and Neck Oncology ( Site 2026), Cheng Du, Sichuan

Tianjin Medical University Cancer Institute & Hospital-lymphoma ( Site 2019), Tianjin, Tianjin

Institute of hematology&blood disease hospital-Lymphoma ( Site 2005), Tianjin, Tianjin

Xinjiang Medical University Cancer Hospital - Urumqi ( Site 2014), Urumqi, Xinjiang

The first Affiliated Hospital, Zhejiang University School of Medicine-Hematology ( Site 2002), Hangzhou, Zhejiang

Zhejiang Cancer Hospital ( Site 2017), Hangzhou, Zhejiang

Sociedad De Oncología y Hematología Del Cesar SAS-Oncology ( Site 2405), Valledupar, Cesar

IMAT S.A.S ( Site 2401), Monteria, Cordoba

Fundacion Valle del Lili- CIC-Oncology CIC ( Site 2402), Cali, Valle Del Cauca

Fakultni nemocnice Hradec Kralove-IV. interni hematologicka klinika ( Site 0301), Hradec Kralove, Not set

Fakultni nemocnice Olomouc ( Site 0303), Olomouc, Not set

Vseobecna fakultni nemocnice v Praze-I. Interní klinika - klinika hematologie ( Site 0302), Praha 2, Not set

Aalborg Universitetshospital, Syd ( Site 0403), Aalborg, Nordjylland

Roskilde Sygehus-Department of Hematology ( Site 0402), Roskilde, Sjaelland

Odense Universitetshospital-Department of Hematology ( Site 0401), Odense C, Syddanmark

Universitaetsklinikum Ulm. ( Site 0601), Ulm, Baden-Wurttemberg

VK&K Studien GbR ( Site 0607), Landshut, Bayern

Kliniken Maria Hilf ( Site 0603), Mönchengladbach, Nordrhein-Westfalen

InVO Institut für Versorgungsforschung in der Onkologie ( Site 0606), Koblenz, Rheinland-Pfalz

Universitätsklinikum Halle ( Site 0604), Halle, Sachsen-Anhalt

Onkologische Schwerpunktpraxis Kurfuerstendamm ( Site 0600), Berlin, Not set

University Hospital of Alexandroupolis ( Site 0701), Alexandroupolis, Anatoliki Makedonia Kai Thraki

Evangelismos General Hospital of Athens ( Site 0700), Athens, Attiki

General Hospital of Athens "Laiko" ( Site 0704), Athens, Attiki

University Hospital of Ioannina ( Site 0702), Ioannina, Not set

Queen Mary Hospital ( Site 3300), Hong Kong, Not set

Rambam Health Care Campus-Hematology and Bone Marrow Transplantation ( Site 1503), Haifa, Not set

Bnai Zion Medical Center ( Site 1505), Haifa, Not set

Hadassah Medical Center-Hemato-Oncology ( Site 1500), Jerusalem, Not set

Rabin Medical Center ( Site 1504), Petah Tikva, Not set

Sheba Medical Center-Hemato Oncology ( Site 1501), Ramat Gan, Not set

Yitzhak Shamir Medical Center. ( Site 1506), Zerifin, Not set

Nagoya University Hospital ( Site 1907), Nagoya, Aichi

Gunma University Hospital ( Site 1903), Maebashi, Gunma

Hokkaido University Hospital ( Site 1900), Sapporo, Hokkaido

Kobe City Medical Center General Hospital ( Site 1910), Kobe, Hyogo

Tohoku University Hospital ( Site 1901), Sendai, Miyagi

Kindai University Hospital ( Site 1909), Sayama, Osaka

Shimane University Hospital ( Site 1911), Izumo, Shimane

Cancer Institute Hospital of JFCR ( Site 1906), Koto, Tokyo

Chiba Cancer Center ( Site 1905), Chiba, Not set

Kyushu University Hospital ( Site 1914), Fukuoka, Not set

Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital ( Site 1913), Hiroshima, Not set

Okayama University Hospital ( Site 1912), Okayama, Not set

Japanese Red Cross Osaka Hospital ( Site 1908), Osaka, Not set

Yamagata University Hospital ( Site 1902), Yamagata, Not set

University Malaya Medical Centre ( Site 1604), Lembah Pantai, Kuala Lumpur

Hospital Pulau Pinang ( Site 1602), George Town, Pulau Pinang

Queen Elizabeth Hospital ( Site 1603), Kota Kinabalu, Sabah

Centro de Infusion Superare ( Site 2602), Ciudad de México, Distrito Federal

Health Pharma Professional Research S.A. de C.V: ( Site 2608), Ciudad de México, Distrito Federal

Waikato Hospital-Haematology ( Site 3202), Hamilton, Waikato

North Shore Hospital-Department of Haematology ( Site 3200), Auckland, Not set

Aotearoa Clinical Trials ( Site 3201), Auckland, Not set

Akershus Universitetssykehus ( Site 0902), Lørenskog, Akershus

Sykehuset i Vestfold ( Site 0903), Toensberg, Vestfold

Oslo Universitetssykehus Rikshospitalet-Avdeling for blodsykdommer ( Site 0901), Oslo, Not set

Centro Medico Monte Carmelo-Oncology ( Site 2706), Arequipa, Ariqipa

Clínica Anglo Americana ( Site 2701), Lima, Not set

Uniwersytecki Szpital Kliniczny nr 1 w Lublinie-Oddział Hematoonkologii-Transplantacji Szpiku i Chem ( Site 1006), Lublin, Lubelskie

Pratia MCM Krakow ( Site 1007), Krakow, Malopolskie

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Kilinka Onkologii I Hematologii ( Site 1004), Warszawa, Mazowieckie

Uniwersyteckie Centrum Kliniczne-Klinika Hematologii i Transplantologii ( Site 1011), Gdansk, Pomorskie

Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku-Oddział Hematologii i Transplantacji ( Site 1013), Słupsk, Pomorskie

Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 1000), Gliwice, Slaskie

Pratia Onkologia Katowice ( Site 1009), Katowice, Slaskie

Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA w Olsztynie-Oddzial Kliniczny Hematologii ( Site 1005), Olsztyn, Warminsko-mazurskie

Instituto Português de Oncologia de Lisboa Francisco Gentil ( Site 3103), Lisbon, Lisboa

Champalimaud Foundation ( Site 3102), Lisbon, Lisboa

Unidade Local de Saude Gaia/Espinho - Hospital Eduardo Santos Silva ( Site 3107), Vila Nova de Gaia, Porto

Unidade Local de Saude Lisboa Ocidental - Hospital de São Francisco Xavier ( Site 3104), Lisboa, Not set

Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 3106), Lisboa, Not set

Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 3100), Porto, Not set

Netcare Pretoria East Hospital-Alberts Cellular Therapy ( Site 1101), Centurion, Gauteng

Wits Clinical Research ( Site 1102), Johannesburg, Gauteng

Groote Schuur Hospital-Clinical Haematology ( Site 1100), Cape Town, Western Cape

Haemalife ( Site 1105), Kuilsriver, Western Cape

Constantiaberg Haematology ( Site 1106), Plumstead, Western Cape

Institut Català d'Oncologia - L'Hospitalet-Haematology Department ( Site 1207), L'Hospitalet Del Llobregat, Barcelona

HOSPITAL CLÍNIC DE BARCELONA ( Site 1202), Barcelona, Cataluna

HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA ( Site 1208), Majadahonda, Madrid, Comunidad De

HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 1209), Pozuelo de Alarcon, Madrid

hospital universitario de canarias ( Site 1205), La Laguna, Santa Cruz De Tenerife

Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1206), Barcelona, Not set

Hospital Universitario de Salamanca - Complejo Asistencial U-Servicio de Hematologia ( Site 1201), Salamanca, Not set

Karolinska Universitetssjukhuset Solna ( Site 1302), Stockholm, Stockholms Lan

Chang Gung Memorial Hospital at Kaohsiung-Division of Hematology and Oncology ( Site 1702), Kaohsiung, Not set

National Cheng Kung University Hospital ( Site 1700), Tainan, Not set

National Taiwan University Hospital ( Site 1701), Taipei, Not set

Chang Gung Medical Foundation-Linkou Branch ( Site 1703), Taoyuan, Not set

Maharaj Nakorn Chiang Mai Hospital ( Site 1800), Muang, Chiang Mai

Chulalongkorn University ( Site 1802), Bangkok, Krung Thep Maha Nakhon

Faculty of Medicine Siriraj Hospital-Division of Hematology, Department of Medicine ( Site 1801), Bangkok, Krung Thep Maha Nakhon

Naresuan University Hospital ( Site 1804), Muang, Phitsanulok

Songklanagarind hospital ( Site 1803), HatYai, Songkhla

Ankara Universitesi Tip Fakultesi Hastanesi-hematology ( Site 1401), Ankara, Not set

Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 1407), Ankara, Not set

Antalya Egitim ve Arastırma Hastanesi ( Site 1409), Antalya, Not set

Trakya University-Balkan Onkoloji Hastanesi ( Site 1403), Edirne, Not set

Marmara Universitesi Pendik Egitim Arastirma Hastanesi ( Site 1408), Istanbul, Not set

Ege Universitesi Hastanesi ( Site 1404), İzmir, Not set

Ondokuz Mays Üniversitesi ( Site 1410), Samsun, Not set

Southmead Hospital ( Site 3010), Bristol, Bristol, City Of

St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 3006), London, London, City Of

The Churchill Hospital ( Site 3007), Oxford, Oxfordshire

GenesisCare - Bristol ( Site 3011), Bristol, South Gloucestershire

GenesisCare - Cambridge ( Site 3001), Newmarket, Suffolk

GenesisCare - Windsor ( Site 3002), Windsor, Windsor And Maidenhead

Barnet Hospital ( Site 3005), Barnet, Not set

St James's University Hospital ( Site 3004), Leeds, Not set

City Hospital, Nottingham University Hospitals NHS Trust ( Site 3003), Nottingham, Not set

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Learn More ›

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

NCT05512390

Recruiting

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-319 in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL)... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/12/2025

Locations: University of Arizona Cancer Center - Tucson /ID# 247752, Tucson, Arizona +17 locations

Conditions: Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma

Learn More ›

A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period.

NCT06524375

Recruiting

The main purpose of the study is to evaluate if adding venetoclax to participants receiving cBTKi for the 1L CLL can achieve deep durable remissions of undetectable measurable residual disease \[uMRD \< or 10\^-4 in peripheral blood (PB)\] by end of combination treatment (EOCT) to allow off-treatment period. The acronym BRAVE stands for Btki Responders to Achieve deep remission (or off-treatment periods) with VEnetoclax.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/11/2025

Locations: Highlands Oncology Group, Springdale, Arkansas +20 locations

Conditions: Chronic Lymphocytic Leukemia

Learn More ›

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

NCT02846623

Recruiting

This phase II trial studies how well atezolizumab, obinutuzumab, and venetoclax work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma or Richter syndrome that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as atezolizumab and obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy,... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/11/2025

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Chronic Lymphocytic Leukemia, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma

Learn More ›

Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

NCT03986034

Recruiting

Background: The drug venetoclax treats chronic lymphocytic leukemia (CLL). Researchers want to find better treatments for CLL. To do that, they need to learn how the drug affects CLL cancer cells and the immune system. Objective: To learn about genetic changes that happen during treatment of CLL with venetoclax. Eligibility: Adults ages 18 and older with relapsed or refractory CLL after at least 1 prior therapy Design: Participants will be screened under a separate protocol. In Phase 1,... Read More

Gender:

ALL

Ages:

Between 18 years and 85 years

Trial Updated:

08/09/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Chronic Lymphocytic Leukemia

Learn More ›

13 - 24 of 70